{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458279808
| IUPAC_name = [(2''R'')-2,3-Dihydroxypropyl] 2-trimethylazaniumylethyl phosphate <!-- see www.fda.gov/ucm/groups/fdagov-public/@fdagov-foods-gen/documents/document/ucm299330.pdf#page=12 -->
| image = L-alpha-GPC Structural Formula V.1.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = OTC

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 28319-77-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 60M22SGW66
| ATC_prefix = N07
| ATC_suffix = AX02
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 55397
| PubChem = 657272
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID      = 571409
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1567463 
| smiles            = [O-]P(=O)(OC[C@H](O)CO)OCC[N+](C)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI          = 1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey       = SUHOQUVVVLNYQR-MRVPVSSYSA-N

<!--Chemical data-->
| C=8 | H=20 | N=1 | O=6 | P=1 
}}

'''<small>L</small>-Alpha glycerylphosphorylcholine''' ('''alpha-GPC''', '''choline alfoscerate''') is a natural [[choline]] compound found in the brain. It is also a [[parasympathomimetic]] [[acetylcholine]] precursor<ref name="pmid12637119">{{cite journal | vauthors = De Jesus Moreno Moreno M | title = Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial | journal = Clinical Therapeutics | volume = 25 | issue = 1 | pages = 178–93 | date = January 2003 | pmid = 12637119 | doi = 10.1016/S0149-2918(03)90023-3 }}</ref> which has been investigated for its potential for the treatment of [[Alzheimer's disease]]<ref name="Parnetti">{{cite journal | vauthors = Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F | title = Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? | journal = Journal of the Neurological Sciences | volume = 257 | issue = 1–2 | pages = 264–9 | date = June 2007 | pmid = 17331541 | doi = 10.1016/j.jns.2007.01.043 | s2cid = 34661218 }}
</ref> and other [[dementia]]s.<ref name="Doggrell">{{cite journal | vauthors = Doggrell SA, Evans S | title = Treatment of dementia with neurotransmission modulation | journal = Expert Opinion on Investigational Drugs | volume = 12 | issue = 10 | pages = 1633–54 | date = October 2003 | pmid = 14519085 | doi = 10.1517/13543784.12.10.1633 | s2cid = 46175609 }}</ref>

Alpha-GPC rapidly delivers [[choline]] to the brain across the [[blood–brain barrier]] and is a biosynthetic precursor of [[acetylcholine]].<ref name="Parnetti" /> It is a non-prescription drug in most countries. The [[Food and Drug Administration|FDA]] determined that intake of no more than 196.2&nbsp;mg/person/day is considered [[generally recognized as safe]] (GRAS).<ref>{{cite web |url= https://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000419.pdf | archive-url = https://web.archive.org/web/20131224102629/https://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000419.pdf | archive-date = 24 December 2013 |title= Generally Recognized as Safe (GRAS) Determination for the Use of AlphaSize® Alpha-Glycerylphosphoryl Choline | date = 25 January 2012 | publisher = United States Food and Drug Administration }}</ref>

==Research==
An Italian multicentre clinical trial on 2,044 patients suffering from recent stroke were supplied alpha-GPC in doses of 1,000&nbsp;mg/day for 28&nbsp;days and 400&nbsp;mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales (Mathew Scale (MS), Mini Mental State Test (MMST), Crichton Rating Scale (CRS) and the Global Deterioration Scale (GDS)) three of which reached statistical significance.<ref>{{cite journal | vauthors = Barbagallo Sangiorgi G, Barbagallo M, Giordano M, Meli M, Panzarasa R | title = alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial | journal = Annals of the New York Academy of Sciences | volume = 717 | pages = 253–69 | date = June 1994 | pmid = 8030842 | doi = 10.1111/j.1749-6632.1994.tb12095.x }}</ref><ref>{{Cite journal|last1=Traini|first1=Enea|last2=Bramanti|first2=Vincenzo|last3=Amenta|first3=Francesco|date=December 2013|title=Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent|journal=Current Alzheimer Research|volume=10|issue=10|pages=1070–1079|doi=10.2174/15672050113106660173|issn=1875-5828|pmid=24156263}}</ref>{{npsn|date=September 2019}} In trials utilizing alpha-GPC in vascular dementia, alpha-GPC administration was reported to improve performance on psychometric tests and to be well tolerated.<ref>{{Cite journal|last1=Di Perri|first1=R.|last2=Coppola|first2=G.|last3=Ambrosio|first3=L. A.|last4=Grasso|first4=A.|last5=Puca|first5=F. M.|last6=Rizzo|first6=M.|date=July 1991|title=A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia|journal=The Journal of International Medical Research|volume=19|issue=4|pages=330–341|doi=10.1177/030006059101900406|issn=0300-0605|pmid=1916007|s2cid=33715399}}</ref>

Small scale studies focusing on the effects of alpha-GPC on physical performance have also reported that alpha-GPC supplementation can increase maximum power and velocity in specified tests (counter-movement jump test) and increase lower body force (isometric mid-thigh pull test).<ref>{{Cite journal|last1=Bellar|first1=David|last2=LeBlanc|first2=Nina R.|last3=Campbell|first3=Brian|date=2015|title=The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength|journal=Journal of the International Society of Sports Nutrition|volume=12|pages=42|doi=10.1186/s12970-015-0103-x|issn=1550-2783|pmc=4650143|pmid=26582972}}</ref><ref>{{Cite journal|last1=Marcus|first1=Lena|last2=Soileau|first2=Jason|last3=Judge|first3=Lawrence W.|last4=Bellar|first4=David|date=2017|title=Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance|journal=Journal of the International Society of Sports Nutrition|volume=14|pages=39|doi=10.1186/s12970-017-0196-5|issn=1550-2783|pmc=5629791|pmid=29042830}}</ref> In iron deficient women, alpha-GPC supplementation has also been reported to enhance non-heme iron uptake from dietary sources.<ref>{{Cite journal|last1=Armah|first1=Charlotte N.|last2=Sharp|first2=Paul|last3=Mellon|first3=Fred A.|last4=Pariagh|first4=Sandra|last5=Lund|first5=Elizabeth K.|last6=Dainty|first6=Jack R.|last7=Teucher|first7=Birgit|last8=Fairweather-Tait|first8=Susan J.|date=May 2008|title=L-alpha-glycerophosphocholine contributes to meat's enhancement of nonheme iron absorption|journal=The Journal of Nutrition|volume=138|issue=5|pages=873–877|doi=10.1093/jn/138.5.873|issn=1541-6100|pmid=18424594|doi-access=free}}</ref>

== Production ==
Industrially, alpha-GPC is produced by the chemical or enzymatic deacylation of [[phosphatidylcholine]] enriched soya [[phospholipids]] followed by [[Chromatography|chromatographic purification]]. Alpha-GPC may also be derived in small amounts from highly purified soy [[lecithin]] as well from purified sunflower lecithin.

== External links ==
*[https://psychonautwiki.org/wiki/Alpha-GPC Alpha-GPC on PsychonautWiki]

== References ==
{{Reflist|2}}

{{Dietary_supplements}}

{{Acetylcholine receptor modulators}}

{{DEFAULTSORT:Alpha-Gpc}}
[[Category:Cholinergics]]
[[Category:Dietary supplements]]
[[Category:Nutrition]]
[[Category:Vitamins]]
[[Category:Neuropharmacology]]
[[Category:Glycerol esters]]